SCHEMBL2066104

SCHEMBL2066104

O=C1NC(=S)S/C1=C/c1ccccc1N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PIM1 P11309 5/20 0.54
▸ PIM3 Q86V86 2/20 0.52
▸ PIM2 Q9P1W9 2/20 0.52
▸ NAT1 P18440 4/20 0.51
▸ PIK3CG P48736 1/20 0.51
▸ GSK3B P49841 1/20 0.50
▸ CA2 P00918 1/20 0.49
▸ EPHX1 P07099 1/20 0.49
▸ PTP4A3 O75365 3/20 0.48
▸ MYC P01106 1/20 0.48
▸ MAX P61244 1/20 0.48
▸ DRD2 P14416 1/20 0.47
▸ DRD4 P21917 1/20 0.47
▸ DRD3 P35462 1/20 0.47
▸ MAOA P21397 2/20 0.47
▸ MAOB P27338 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10090251 1.00 PIM1 (0.54) PIM1PIM3PIM2NAT1PIK3CG
SCHEMBL2066107 1.00 PIM1 (0.54) PIM1PIM3PIM2NAT1PIK3CG
SCHEMBL2066084 0.88 PTP4A3 (0.60) PIM1NAT1PIK3CGCA2EPHX1
SCHEMBL2066085 0.88 PTP4A3 (0.60) PIM1NAT1PIK3CGCA2EPHX1
SCHEMBL10090257 0.88 PTP4A3 (0.60) PIM1NAT1PIK3CGCA2EPHX1
SCHEMBL10090250 0.82 NAT1 (0.60) PIM1PIM3PIM2NAT1GSK3B
SCHEMBL2065290 0.82 NAT1 (0.60) PIM1PIM3PIM2NAT1GSK3B
SCHEMBL2065291 0.82 NAT1 (0.60) PIM1PIM3PIM2NAT1GSK3B
SCHEMBL885537 0.80 MEN1 (0.60) PIM1PIM3PIM2NAT1GSK3B
SCHEMBL10090249 0.80 MEN1 (0.60) PIM1PIM3PIM2NAT1GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US claimed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US claimed
US-8148541-B2 Rhodanine derivatives, a process for the preparation thereof and pharmaceutical composition containing the same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2012-04-03 — — US disclosed
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2009-02-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042872-A1 Rhodanine Derivatives, a Process for the Preparation Thereof and Pharmaceutical Composition Containing the Same PTPRR, PTPRG, PTPRS PIM1 2536/4885PIM3 1531/4885PIM2 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback